Analyzing ProQR Therapeutics N.V. (PRQR) By Technical Indicators

0
1

At the last check on Friday, ProQR Therapeutics N.V.’s (NASDAQ:PRQR) stock was down -$0.05, moving down -3.70 percent to $1.30. The average number of shares traded per day over the past five days has been 1,684,666 shares. 4 times new highs have been achieved over the past 5 days, with a $0.2100 gain in that time frame. In the last twenty days, the average volume was 1,175,937, while in the previous 50 days, it was 794,501.

Since last month, PRQR stock rose 45.18%. Shares of the company fell to $0.8553 on 11/09/22, the lowest level in the past month. A 52-week high of $8.60 was reached on 01/04/22 after having rallying from a 52-week low of $0.53. Since the beginning of this year, PRQR’s stock price has dropped by -83.15% or -$6.7000, and marked a new high 2 times. However, the stock has declined by -84.88% since its 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Valuation Metrics

The stock’s beta is 0.93. Besides these, the trailing price-to-sales (P/S) ratio of 20.54, the price-to-book (PB) ratio of 1.44.

Financial Health

In the three months ended June 29, ProQR Therapeutics N.V.’s quick ratio stood at 3.90, while its current ratio was 3.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.29, and the total debt-to-equity ratio was 0.34. Based on annual data, PRQR earned $69.27 million in gross profit and brought in $1.6 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -32.90%. Return on equity (ROE) for the past 12 months was -78.40%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected ProQR Therapeutics N.V. to report -$0.21 quarterly earnings, the actual figure was -$0.2 per share, beating the consensus estimate by 4.80%. During the quarter, the company generated -$19.27 million in EBITDA. The liabilities of ProQR Therapeutics N.V. were 57.6 million at the end of its most recent quarter ended June 29, and its total debt was $60.93 million.

Technical Picture

This quick technical analysis looks at ProQR Therapeutics N.V.’s (PRQR) price momentum. With a historical volatility rate of 86.47%, the RSI 9-day stood at 81.46% on 23 November.

With respect to its five-day moving average, the current ProQR Therapeutics N.V. price is up by +19.09% percent or $0.2100. At present, PRQR shares trade +41.61% above its 20-day simple moving average and +58.77% percent above its 100-day simple moving average. However, the stock is currently trading approximately +65.86% above its SMA50 and -77.61% below its SMA200.

Stochastic coefficient K was 88.37% and Stochastic coefficient D was 91.16%, while ATR was 0.1008. Given the Stochastic reading of 83.48% for the 14-day period, the RSI (14) reading has been calculated as 79.54%. As of today, the MACD Oscillator reading stands at 0.1600, while the 14-day reading stands at 0.2546.

Analyst Ratings

ProQR Therapeutics N.V. downgraded its rating on ProQR Therapeutics N.V. (NASDAQ: PRQR) to a Neutral in a note to investors on February 14, 2022. The analysts firm previously had a Buy rating on the stock.

LEAVE A REPLY

Please enter your comment!
Please enter your name here